— Sunesis Pharmaceuticals (NASDAQ: SNSS) reported loss of $0.05 per share in the fourth quarter of 2019, vs $0.07 per share loss expected.
— Net revenue rose to $2.1 billion, vs. $310,000 expected. The growth in topline was driven by revenue recognized from the upfront payments received under the license agreements with DOT-1 and Denovo.
— Cash and cash equivalents rose to $34.6 million, from $13.7 million a year ago. The growth was primarily due to net proceeds from the issuance of common and preferred stock, and proceeds from the SVB loan.
— SNSS shares fell over 2% immediately following the announcement.
Most Popular
Here’s a look at Dollar Tree’s (DLTR) expectations for the remainder of the year
Shares of Dollar Tree Inc. (NASDAQ: DLTR) were down over 1% on Wednesday, a day after the company reported earnings results for the third quarter of 2022. Revenue and earnings
Target Corporation (TGT): A look at how the retail giant is shaping up against an inflationary backdrop
Shares of Target Corporation (NYSE: TGT) were up over 1% on Wednesday. The stock has dropped 30% year-to-date and 35% over the past 12 months. Last week the company reported
Is Zoom Video Communications (ZM) a good investment after Q3 earnings?
Zoom Video Communications (NASDAQ: ZM) expanded its customer base at an accelerated pace during the COVID crisis and soon became the preferred video conferencing platform for businesses and millions of
